跳转到主要内容

快速连接

白皮书

Product Alert – Daprodustat

Product Alert – Daprodustat

Daprodustat is a potent reversible inhibitor of hypoxia-inducible factor (HIF)-prolyl hydroxylase (PH) 1, PH2 and PH3, with an IC50 in the low nM range. By inhibiting HIF-PHDs, Daprodustat promotes the stabilisation and nuclear accumulation of HIF-1α and HIF-2α transcription factors.

Dr. Reddy's API Offering*

Targeting CS01 form - Lab samples and COA are available.

  • Reliable KSM suppliers were added to ensure timely deliveries and adherence to stringent specifications.
  • We are planning adequate capacity to supply development quantity in a short lead time.
  • cGMP API manufacturing facilities, successfully inspected by TGA, WHO GMP, KFDA, PMDA, Health Canada, ANVISA & USFDA.
  • Planning USDMF by December 2024.

To learn more about our API offerings, please read the Tech sheet on Daprodustat API by filling out the contact form below.

Note: *Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale.

Explore other Whitepapers:

Know More

Download Now

请填写下面的联系表以查看白皮书

给我们发电子邮件: api@drreddys.com | +91 40 49002222

免责声明

本目錄中的任何信息(包括對任何產品或服務的任何引用)均不構成銷售要約,或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是,只要存在此類監管豁免,就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估,並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途,但可用於第 107A 節。